产品
编 号：F750547
分子式：C29H37ClFN9O3
分子量：614.11
分子式：C29H37ClFN9O3
分子量：614.11
产品类型
规格
价格
是否有货
结构图
CAS No: 2250024-74-7
产品详情
生物活性：
DDO-2093 is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC50=8.6 nM; Kd=11.6 nM) with antitumor activity. DDO-2093 selectively inhibits the catalytic activity of MLL complex.
体内研究：
DDO-2093 (20-80 mg/kg; i.p.; every other day for 21 days) significantly suppresses the tumor size and weight in a dose-dependent manner.Animal Model:Female nude mice (MV4-11 human leukemia cancer xenografts)
Dosage:20 mg/kg, 40 mg/kg and 80 mg/kg
Administration:Intraperitoneal injection; every other day for 21 days
Result:Had the tumor volume growth inhibition (GI) values were calculated to be 13.7%, 37.6% and 63.9% with doses of 20 mg/kg, 40 mg/kg and 80 mg/kg, respectively.
体外研究：
DDO-2093 (5 μM; pretreated 7 days) inhibits MLL-fusion protein dependent genes expression (HOXA9 and Meis1).
DDO-2093 is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC50=8.6 nM; Kd=11.6 nM) with antitumor activity. DDO-2093 selectively inhibits the catalytic activity of MLL complex.
体内研究：
DDO-2093 (20-80 mg/kg; i.p.; every other day for 21 days) significantly suppresses the tumor size and weight in a dose-dependent manner.Animal Model:Female nude mice (MV4-11 human leukemia cancer xenografts)
Dosage:20 mg/kg, 40 mg/kg and 80 mg/kg
Administration:Intraperitoneal injection; every other day for 21 days
Result:Had the tumor volume growth inhibition (GI) values were calculated to be 13.7%, 37.6% and 63.9% with doses of 20 mg/kg, 40 mg/kg and 80 mg/kg, respectively.
体外研究：
DDO-2093 (5 μM; pretreated 7 days) inhibits MLL-fusion protein dependent genes expression (HOXA9 and Meis1).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备